Pharmaceuticals
Herbalgy, the Pain Management Expert, Partners with Heroes in White to Champion a "Pain-Relieving Serenity" Lifestyle
Bringing the Wisdom of Traditional Chinese Medicine into Modern Living HONG KONG, Oct. 9, 2025 /PRNewswire/ -- Following the phenomenal success of TVB's widely acclaimed TV dramaHeroes in White—the top-rated series of 2025 with an audience of over 1.57 million and a rating of 24.2 points—Herbalgy...
2025-10-09 14:18
1985
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology
* The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized, double-blind and placebo-controlled Phase III trial of etrasimod conducted acrossAsia. The study included a 12-week induction phase followed by a 40-week maintenance phase and represents the large...
2025-10-09 13:10
2136
New White Paper by APAC CVD Alliance and Deloitte Charts Path to Tackle Rising Heart Failure Burden in Asia-Pacific
* 32 million people in Asia-Pacific live with heart failure, and this number is rising fast. * New blueprint targets a 20% cut in hospitalisations and 15% boost in survival rates within 5 years. * Urgent call for early diagnosis, digital and community-based care, and sustainable financing t...
2025-10-08 09:00
2355
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025
* Details of the Phase 3 MASCOT trial investigating amlenetug for the treatment of patients with Multiple System Atrophy (MSA) will be presented at the International Congress of Parkinson's Disease and Movement Disorders® 2025 1-3 * MSA is a rare, rapidly progressing, neurodegenerative disease...
2025-10-02 16:41
2089
Major Health Management Wins the 2025 Health Brand Awards - Excellence Award in Health Technology (Health Examination Platform): 38 Years of Quality Commitment, Transforming into a Leading Health Technology Pioneer
TAIPEI, Oct. 1, 2025 /PRNewswire/ -- Taiwan's leading health management brand, Major Health Management, has been honored with the Excellence Award in Health Technology – Health Examination Platform at the 2025 Health Brand Awards. This award is a highly regarded annual recognition in the health i...
2025-10-01 14:51
2498
Telix Announces Record-Breaking Presence at EANM 2025
MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (E...
2025-10-01 13:57
2861
Novartis Singapore and the Singapore Heart Foundation Launch 'Beat the Block' Campaign to Raise Awareness of High Blood Cholesterol
* Local survey reveals critical misconceptions and gaps in blood cholesterol management among people living inSingapore. * Almost one in three deaths in Singapore is attributed to cardiovascular disease, underscoring the urgent need to improve blood cholesterol management. [1] * Beat the Blo...
2025-09-30 10:00
1744
Johnson & Johnson Launches "Dual Control" Campaign in Asia Pacific to Empower Patients with IBD to Balance Disease Management and Dreams
New IBD research shows that, even during clinical remission, people living with Crohn's diseasecontinue to experience greater work impairment than the general population The new campaign aims to empower patients to take dual control of disease management and life aspirations by striving for endo...
2025-09-30 10:00
3228
Health Hope Pharma Enters into Exclusive Licensing Agreement with Gilead Sciences
* HHP and Hanmi will grant Gilead exclusive license to encequidar, and provide access to drug supply HONG KONG, Sept. 29, 2025 /PRNewswire/ -- Health Hope Pharma Limited ("HHP") today announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("...
2025-09-29 20:48
2164
Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN), today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisition...
2025-09-29 12:58
3137
Tourism Malaysia and MHTC Bring Malaysia Fair 2025 to Surabaya A Celebration of Culture, Cuisine, Travel, and Healthcare Excellence
SURABAYA, Indonesia, Sept. 26, 2025 /PRNewswire/ -- Tourism Malaysia, in collaboration with the Malaysia Healthcare Travel Council (MHTC), proudly presents Malaysia Fair 2025—a four-day celebration ofMalaysia's culture, cuisine, tourism, and healthcare excellence. Taking place at Pakuwon Mall, Su...
2025-09-26 09:45
4191
ADVANCION PUBLISHES 2024 CORPORATE SUSTAINABILITY REPORT
Fourth annual report highlights continued progress in sustainable innovation, safety, and responsible resource stewardship BUFFALO GROVE, Ill., Sept. 25, 2025 /PRNewswire/ -- Advancion Corporation ("Advancion" or "Company"), a global leader in life science buffers and proprietary specialty ingre...
2025-09-25 02:40
2767
The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)
* Cardiovascular disease (CVD) kills nearly 18 million people each year, more than all cancers combined1,2 * Elevated lipoprotein(a) or Lp(a), an inherited condition that raises CVD risk, affects 1 in 5 people worldwide but is rarely tested3 * New survey across Asia Pacific and Middle East s...
2025-09-24 20:21
2514
Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
SHANGHAI, Sept. 24, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Glenmark Specialty S.A. (GSSA), a whol...
2025-09-24 19:45
3466
Xinhua Silk Road: Guotai Haitong Securities hosts conference on biopharma and AI in E. China's Shanghai
BEIJING, Sept. 24, 2025 /PRNewswire/ -- The 2025 Shanghai pioneering industries conference, hosted by Guotai Haitong Securities, was recently held in east China's Shanghai. The event also featured the 14th pharmaceutical CEO forum and the 5th artificial intelligence (AI) conference. The event bro...
2025-09-24 09:02
3123
TraceLink Delivers Intelligent Productivity Gains with OPUS Platform Expansion
BOSTON, Sept. 24, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced powerful new capabilities in its Orchestration Platform for Universal Solutions (OPUS) designed to unlock unprecedented productivity...
2025-09-24 00:12
1938
LabConnect Partners with The Bracken Group to Expand Radiopharmaceutical Support Services
JOHNSON CITY, Tenn., Sept. 23, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, announces a strategic collaboration with The Bracken Group to enhance its radiopharmaceutical support capabilities. As demand for radiopharmac...
2025-09-23 21:15
1738
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics
2025-09-23 20:01
2002
Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- The 2025 European Society for Medical Oncology (ESMO) Congress will take place inBerlin, Germany, from October 17 to 21. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) will present results from multiple clinical stud...
2025-09-23 17:03
2658
Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC
CHENGDU, China, Sept. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for review ...
2025-09-23 10:22
2137
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 280 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
22310
Luckin Coffee Celebrates 100 Stores in Singapore
2026-09-28 14:31
5925
